HIV drug Tivicay is expected to become cheaper in China under a recent manufacturing deal between ViiV and Desano. The Chinese firm expects to gain a 35% share of the global generic antiretroviral API supply market this year after patent licensing agreements with the Medicines Patent Pool.

Among the 113 listed pharma in China, more than two thirds reported sales growth in the first three quarters of the year.

A U.S. District Court judge for the Eastern District of New York said that China’s five largest vitamin C producers will be on trial in the U.S. for price manipulation allegations.